Avita Medical, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, RCEL reported earnings of -0.46 USD per share (EPS) for Q3 25, missing the estimate of -0.28 USD, resulting in a -58.78% surprise. Revenue reached 17.06 million, compared to an expected 18.55 million, with a -8.00% difference. The market reacted with a +10.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.37 USD, with revenue projected to reach 18.19 million USD, implying an decrease of -19.57% EPS, and increase of 6.64% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Avita Medical, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Avita Medical, Inc. Common Stock reported EPS of -$0.46, missing estimates by -58.78%, and revenue of $17.06M, -8% below expectations.
How did the market react to Avita Medical, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 10.88%, changed from $3.40 before the earnings release to $3.77 the day after.
When is Avita Medical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Avita Medical, Inc. Common Stock's next earnings report?
Based on 7
analysts, Avita Medical, Inc. Common Stock is expected to report EPS of -$0.37 and revenue of $18.19M for Q4 2025.